Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $209

Morgan Stanley analyst Matthew Harrison maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $170 to $209.

byBenzinga Newsdesk

December 16, 2022

1 minute read

Morgan Stanley analyst Matthew Harrison maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $170 to $209.

Roche-AC Immune’s Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer’s Patients

By Vandana Singh

Today, 3:04 AM

Roche Holdings AG (OTC:RHHBY) said its Alzheimer’s medicine crenezumab did not slow or prevent cognitive decline in people with a specific…

ACIU

SVB Leerink Initiates Coverage On Universal Health Services with Market Perform Rating, Announces Price Target of $140

By Benzinga Newsdesk

Today, 3:04 AM

SVB Leerink analyst Whit Mayo initiates coverage on Universal Health Services (NYSE:UHS) with a Market Perform rating and announces Price Target of $140.

UHS

Truist Securities Maintains Buy on Etsy, Lowers Price Target to $112

By Benzinga Newsdesk

Today, 3:04 AM

Truist Securities analyst Naved Khan maintains Etsy (NASDAQ:ETSY) with a Buy and lowers the price target from $150 to $112.

ETSY

The Vita Coco Company CFO Kevin Benmoussa To Depart Later This Year

By Bill Haddad

Today, 3:04 AM

NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ:COCO) ("Vita Coco" or the "Company"), a leading high-growth platform of better-for-you beverage brands, today announced

COCO

Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $209

Related Posts

Roche-AC Immune’s Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer’s Patients

SVB Leerink Initiates Coverage On Universal Health Services with Market Perform Rating, Announces Price Target of $140

Truist Securities Maintains Buy on Etsy, Lowers Price Target to $112

The Vita Coco Company CFO Kevin Benmoussa To Depart Later This Year